Boehringer's Spiriva inhaler now available throughout the U.S.; Update on Mannkind's inhaled insulin from JP Morgan;

> Boehringer Ingelheim's Spiriva Respimat inhaler is now available by prescription in pharmacies throughout the U.S. Release

> Mannkind's new CEO, Hakan Edstrom, gave an update on its inhaled insulin product at the JP Morgan Healthcare Conference. Afrezza is going to launch in partnership with Sanofi ($SNY). "In terms of the early market initiation, basically, we are looking at the insulin intensification of those patients that have been on a long acting initially to just avoid frequent injections and certainly those that are failing on orals and need to start an insulin therapy," he said. Listen

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.